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A New Millennium and a New Editor
It is both an honor and a privilege to become the 12th
editor of The American Journal of Human Genetics. As
we move into the new millennium, human genetics will
continue to play an increasingly important and pervasive
role in medicine and biology, and the Journal will con-
tinue to be our record of these historical times. I hope
to maintain the course steered by our previous editors,
with the focus of the Journal continuing to be the pub-
lication of the very best our field has to offer, as well as
preservation of the richness of experimental diversity;
the Journal is unique among similar journals for re-
porting such a breadth of scientific inquiry in human
genetics. Soon we will have the draft euchromatic se-
quence of the human genome, which will forever change
how the study of normal and abnormal variation in hu-
mans is carried out. Indeed, the next 5 years should
illuminate the power of genomic-based analysis, and it
will truly be an exciting time to be a human geneticist.
Editorial change is healthy, since it allows a fresh look
at all aspects of the Journal. I am extremely fortunate
to be taking over a journal with few, if any, problems.
The past 5 years have led to unparalleled growth in the
Journal. Peter Byers not only oversaw the manuscript
review process at a time when the Journal enjoyed the
receipt of many more high-quality manuscripts than it
could ever hope to publish (not a trivial feat, as I am
rapidly discovering), but he fundamentally changed the
Journal for the better. The speed of publication, the com-
modity of all top-flight journals, has substantially in-
creased under Peter’s stewardship. Moreover, he has set
in motion further changes, chiefly with The University
of Chicago Press, that will continue to diminish the time
from submission to publication, long after his tenure as
editor has expired. Peter also led the Journal into the
electronic era, as it became one of the first biomedical
journals to publish articles electronically long before the
entire issue was ready for press. His mark on the Journal
will be indelible.
Peter and his staff, principally Roberta Wilkes and
John Ashkenas, have made the transition of the editorial
offices over 2,000 miles a relatively painless process. Fol-
lowing Peter’s example of hiring Roberta away from the
then dean of medicine at the University of Washington,
I was fortunate to attract the new managing editor, Ca-
thy Alden, away from my executive vice president for
health affairs. Both hirings clearly made the upper ad-
ministrations well aware of the presence of the Journal
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at their institutions. Cathy and I have now assembled
what should prove to be a very able team in the editorial
office that includes Carissa Craig as the assistant man-
aging editor and Dr. Kathryn Beauregard as the editorial
fellow. I am pleased to report that the Atlanta office is
running relatively smoothly despitemy inexperience run-
ning a major journal. Thank you, Peter.
Although the Journal is not in need of fixing, we can-
not help but tinker with it slightly to make it, we hope,
more user friendly. First are format changes. Our “Let-
ters to the Editor” section has metamorphosed into short
reports on original studies. Although this is a natural
evolution in many journals, it has somewhat obscured
the more traditional role of the “Letters” section, such
as commentary on previously published papers as well
as a general forum on issues of importance to our society
or to human genetics in general. Accordingly, we will
now initiate a “Reports” section for the presentation of
brief original research of particular timeliness and sig-
nificance. The format will remain essentially the same
as the “Letters” section (i.e., no subdivisions within the
text) but will be limited to four journal pages, including
the addition of a 200-word abstract. This will allow
better access to the data, by providing the abstractswhen
PubMed searches are performed. The “Letters to the
Editor” section will remain but no longer will include
letters reporting original research.
A second change being instituted in the Journal are
modifications aimed at improving our speed of publi-
cation, both in real time and in perception. The dates
from submission to publication are carefully scrutinized
by authors when they are deciding where to submit. We
at the Journal must diminish this interval by examining
new submissions quickly and, if they are appropriate for
the Journal, by rapidly soliciting reviewers. Your part,
as reviewers, will be to help speed up this process, with-
out compromising scientific evaluation. We have now
established a 10-day turnaround for reviews; although
this is not always possible, it is the goal that we strive
for. Ideally, an author should be able to receive the re-
views and editorial decision within 2 weeks. With The
University of Chicago Press, our goal is to be able to
electronically publish an accepted, final manuscript
within 3 weeks. Thus, without revision, we should be
able to routinely go from submission to publication in
35 days. Of course, manuscripts are almost never ac-
cepted without revision. The time of revision is a period
largely out of the control of the editorial office and is
the authors’ responsibility. In the past, we have been
more than generous with revision time, with some au-
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Figure 1 Submission and publication statistics for the past dec-
ade. The number of submissions to the Journal is shown in red, and
the total number of articles and letters published is shown in blue.
thors taking nearly a year for revision. Obviously, a few
such papers could wreak havoc with our submission-to-
publication interval. Given the pace of human genetics
research, the level of significance of a manuscript dra-
matically changes over a period of only a couple of
months. Therefore, we will allow, in general, only 4
weeks for return of a revised manuscript. If additional
experimentation is required, this time period can be ex-
tended, but for no more than a total of 8 weeks; after
that time, the manuscript must be resubmitted as a new
contribution. This will be without prejudice to the newly
submitted manuscript, although such manuscripts will
likely require rereview. This change alone should place
the Journal among the most expedited journals in the
field.
To allow even more rapid publication of the occa-
sional superior article/report of extremely high signifi-
cance and timeliness, we will institute a fast-track for-
mat. For manuscripts of such significance, we will
perform a 24–48-hour review, after discussion, between
the editor and the corresponding author, regarding the
suitability of the manuscript for this track. We have al-
ready had our first experiences with this track, resulting
in one instance in which the reviews were sent back to
the authors for revision within 20 hours of receipt of
the manuscript. It is anticipated that very few manu-
scripts will reach this level of significance, and suitability
will not be judged solely on competitive issues but,
rather, on the impact that the finding has on the field in
general. For those papers judged suitable and scientifi-
cally sound, the entire process will be expedited, moving
the completed manuscript in the front of the queue for
publication. Given the burden that such manuscripts
represent for the editorial office and the reviewers, who
will be drawn mostly from the ranks of the associate
editors, authors would be well advised to carefully and
objectively consider the suitability of identifying such a
manuscript before contacting the editor.
As the field of human genetics moves into the new
millennium, the Journal must be flexible as the func-
tional genomics and proteomics become more central in
the study of human variation. Since the experimental
dissection of function often requires in vivo studies,
sometimes not possible in humans, we will welcome pa-
pers utilizing model organisms to address questions cen-
tral to human and medical genetics. Although these pa-
pers will most often involve mice, we anticipate that the
yeast, worm, and fly will become more prevalent in hu-
man genetic inquiry. The clear relationship of such stud-
ies to the human will be mandatory, and, in particular,
the conclusions drawn from such studies must directly
add to our knowledge of the human condition, in order
to be appropriate for publication in the Journal.
As the number of quality papers submitted steadily
increases (fig. 1) the Journal must become increasingly
selective. As a practical matter, the number of pages pub-
lished has reached the limit of both fiscal and personnel
constraints. More importantly, our success allows our
selectivity to increase such that papers considered for
review must demonstrate a significant increase in knowl-
edge, beyond simple incremental advances. Papers re-
porting essentially negative data will join papers of sim-
ple mutational reports, in not meeting the minimal
competitive level for consideration, and will be returned
without review unless they clearly demonstrate marked
significance. Likewise, linkage papers will receive greater
scrutiny such that manuscripts with overly large map-
ping intervals or exceedingly rare conditions (i.e., a sin-
gle family known with the disorder) may not reach suf-
ficient priority unless they are of compelling interest and
significance. Manuscripts reporting statistical or popu-
lation studies should also go well beyond incremental
advances, reporting data or approaches of substantial
impact. This is not to say that contributions declined by
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the editorial office are not worthy of publication. Since
we can publish only approximately 20%–30% of the
manuscripts received, and since a rough guess might
be that just 10% or so of the received manuscripts are
scientifically unsuitable or of limited interest to the read-
ership, we must therefore decline an astounding
60%–70% of manuscripts that report well-done studies
and that are of interest and utility to those working in
the field. However, as we rise to the top tier of genetics
journals, we unfortunately must refer such manuscripts
to the many other fine journals within our field. Thus,
priority and balance among the manuscripts become in-
creasingly important issues relating to significance of
publication. Thus, authors would be well advised to
carefully craft their manuscripts to impart the major sig-
nificance and general interest of their findings to the
reader. As always, clearly written manuscripts telling a
compelling story fare best.
The next few years will not be without controversy
and challenges for biomedical publications. The devel-
opment of PubMed Central as a repository for electronic
versions of journals will be a significant issue in the
coming months. On the one hand, PubMed Central will
allow open and readily accessible access to journals and,
importantly, to the cited references themselves. This
clearly would be a major advance in how we and our
colleagues carry out our work. On the other hand, such
open access could lead to a loss of library subscriptions
and the derived revenue. The process of putting together
the Journal is a costly endeavor, and, without this rev-
enue stream, page charges to authors could escalate to
dizzying heights. We will strive to do the right thing
professionally while maintaining a sense of fiduciary re-
sponsibility for the Journal. To this end, Peter Byers and
I have decided to make the electronic version of the
Journal open to everyone, over the Web, 1 year after
publication. We believe that this will have little impact
on our subscription base and yet will provide everyone
complete access to the Journal, within 1 year of the issue
publication. We can therefore be proud that our Journal
was among the first to be available as an electronic jour-
nal and that it now is also among very few journals with
open Web access after defined publication intervals. We
will continue to take advantage of Web-based capabil-
ities, as we have with transmittal of galley proofs to
authors electronically. We anticipate that in the coming
year, for example, peer review will be carried out largely
electronically, as will manuscript submission.
So, we move on together into the year 2000 and can
look forward to tremendous advances in human genetics
and to the recording of those advances in our Journal.
Although the declaration of the golden age of genetics
is now decades old, I, for one, believe the best is yet to
come.
STEPHEN T. WARREN
Editor
